Teva Reports Promising Early Results for Celiac Disease Drug
How 3 Israeli newsrooms covered this story — translated into English and compared side by side.
By מערכת ice
First reported by Bizportal · 1 hour ago
What happened
Teva Pharmaceuticals has announced promising early results from a Phase 2a clinical trial for its experimental drug TEV-408, showing it significantly reduced intestinal damage in celiac disease patients exposed to gluten. The drug, which targets the IL-15 protein, was well-tolerated and also showed improvements in inflammation and symptoms, offering potential beyond the current gluten-free diet.
- 01Teva's experimental drug TEV-408 shows positive early results in celiac disease trial.
- 02Drug significantly reduced gluten-induced intestinal damage compared to placebo.
- 03TEV-408 also decreased inflammation and improved GI symptoms.
- 04The drug is an antibody blocking the IL-15 protein involved in inflammation.
- 05FDA granted TEV-408 Fast Track designation for celiac disease treatment.
- 06Teva is also developing the drug for vitiligo.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 3 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
